ABIOMED INC Form 8-K May 02, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 2, 2013

(Date of earliest event reported)

ABIOMED, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other Jurisdiction

04-2743260 (IRS Employer

	of Incorporation) 001-0	Identification Number)
(Commission		
File Number)		
22 Cherry Hill Drive		
Danvers, MA 01923		
(Address of Principal Executive Offices, including Zip Code)		
(978) 646-1400		
(Registrant s Telephone Number, including Area Code)		
Not Applicable		
(Former Name or Former Address, if Changed Since Last Report)		
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of		
he following provisions:		
	Written communications pursuant to Rule 425 under the Securities	Act (17 CFR 230.425)
•	Soliciting material pursuant to Rule 14a-12 under the Exchange Ac	t (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) und	ler the Eychange Act (17 CFR 240 14d-2(b))
	The commencement communications pursuant to Rule 1 to 2(b) and	for the Exchange Net (17 CTR 210.11 to 2(0))
	Pre-commencement communications pursuant to Rule 13e-4(c) und	er the Exchange Act (17 CFR 240.13e-4(c)

Item 2.02 Results of Operations and Financial Condition.

On May 2, 2013, we issued a press release reporting our financial results for our fourth quarter and fiscal year ended March 31, 2013. A copy of the press release is set forth as Exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Description

99.1 Press release dated May 2, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Abiomed, Inc.

By: /s/ Robert L. Bowen Robert L. Bowen Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

Date: May 2, 2013

Exhibit Index

Exhibit

Number Description

99.1 Press release dated May 2, 2013.